Adelong Gold (ASX:ADG) has engaged a new exploration consultant to advance the Adelong Gold Project. Initial soil sampling has revealed promising indications of arsenic and antimony, suggesting potential gold mineralisation. A drilling program is now being planned to further explore these findings. Shares are trading 11.11 per cent higher at 0.5 cents.
Adacel Technologies (ASX:ADA) has successfully retained the FAA contract for Tower Simulation System Support & Technical Refresh. The contract, valued at USD$59 million, will involve comprehensive maintenance and upgrades, and Adacel anticipates generating EBITDA between $4 million and $5 million in FY2025. Shares are trading 13.64 per cent higher at 50 cents.
Neurotech International (ASX:NTI) has announced that NTI164, the company's proprietary drug formulation derived from a unique cannabis strain with low THC, has been shown to reverse immune dysregulation in PANDAS/PANS children, as evidenced by genomic analysis. This suggests that the drug has the potential to improve the overall health and functional outcomes of children with these conditions. Shares are trading 7.35 per cent higher at 7.3 cents.
Adelong Gold (ASX:ADG) has engaged a new exploration consultant to advance the Adelong Gold Project. Initial soil sampling has revealed promising indications of arsenic and antimony, suggesting potential gold mineralisation. A drilling program is now being planned to further explore these findings. Shares are trading 11.11 per cent higher at 0.5 cents.
阿德隆黃金（澳大利亞證券交易所股票代碼：ADG）已聘請了一位新的勘探顧問來推進阿德隆黃金項目。初步的土壤採樣顯示出砷和銻的良好跡象，表明潛在的金礦化。目前正在計劃一項鑽探計劃，以進一步探索這些發現。股價上漲11.11％，至0.5美分。
Adacel Technologies (ASX:ADA) has successfully retained the FAA contract for Tower Simulation System Support & Technical Refresh. The contract, valued at USD$59 million, will involve comprehensive maintenance and upgrades, and Adacel anticipates generating EBITDA between $4 million and $5 million in FY2025. Shares are trading 13.64 per cent higher at 50 cents.
Adacel Technologies（澳大利亞證券交易所股票代碼：ADA）成功保留了美國聯邦航空局的塔式仿真系統支持和技術更新合同。該合同價值5900萬美元，將涉及全面的維護和升級，Adacel預計 FY2025 的息稅折舊攤銷前利潤將在400萬至500萬美元之間。股價上漲13.64％，至50美分。
Neurotech International (ASX:NTI) has announced that NTI164, the company's proprietary drug formulation derived from a unique cannabis strain with low THC, has been shown to reverse immune dysregulation in PANDAS/PANS children, as evidenced by genomic analysis. This suggests that the drug has the potential to improve the overall health and functional outcomes of children with these conditions. Shares are trading 7.35 per cent higher at 7.3 cents.
Neurotech International（澳大利亞證券交易所股票代碼：NTI）宣佈，該公司的專有藥物配方 NTI164 源自一種獨特的低四氫大麻毒株，已被證明可以逆轉PANDAS/PANS兒童的免疫失調，基因組分析證明了這一點。這表明該藥物有可能改善患有這些疾病的兒童的整體健康和功能結果。股價上漲7.35％，至7.3美分。
